Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a report released on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Other research analysts also recently issued research reports about the stock. JMP Securities reaffirmed a market outperform rating and set a $6.00 price objective on shares […]

Leave a Reply

Your email address will not be published.

Previous post Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated at StockNews.com
Next post StockNews.com Initiates Coverage on Fiesta Restaurant Group (NASDAQ:FRGI)